Genomics and Vertex Extend Drug Discovery Partnership Worth $220 Million
Genomics Limited has extended its strategic drug discovery collaboration with Vertex Pharmaceuticals for another four years, strengthening a partnership focused on using human genetics to identify new drug targets and develop precision medicines.
Announced on November 18, 2026, the agreement builds on an existing eight-year collaboration that began in 2018. The extended partnership has a potential value of more than $220 million, depending on the achievement of research, development, regulatory and commercial milestones. Genomics will also be eligible for tiered royalties on future net sales of products that may result from the collaboration.
Under the agreement, scientists from both companies will continue working together to use human genetic information to discover and validate new drug targets. The research will also focus on selecting biomarkers for precision medicines and understanding how genetic differences can influence disease development and treatment outcomes.
Human genetics plays an important role in drug discovery because it can help researchers understand the biological causes of diseases and identify proteins or pathways that could be targeted with new medicines. This approach may also help pharmaceutical companies select drug candidates with stronger scientific evidence before moving them into clinical development.
Genomics will contribute its large-scale genetic and health data resources, along with its proprietary analytical tools and technology platform, Mystra. The platform combines genetic information with health data to provide insights into human biology and disease mechanisms.
According to the company, its data collection includes more than 45,000 genome-wide association studies (GWAS) and trillions of rows of data. These resources help researchers study relationships between genetic variations and different diseases.
In June 2026, Genomics launched Mystra AI, an AI-powered interface designed to support scientists in analysing complex genetic information and accelerating research and development activities.
The company has also identified more than 100 potential drug targets across several disease areas, including cancer, heart disease and diabetes, using its data platform and proprietary research tools.
Mark Bunnage, Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals, said the company’s understanding of human genetics and disease biology is central to discovering and developing new treatments. He described Genomics as a valuable research partner and welcomed the extension of the collaboration.
Professor Sir Peter Donnelly, Co-founder and Chief Executive Officer of Genomics, said the partnership has demonstrated the value of human genetics in identifying and validating drug targets. He added that the extended agreement will help both companies expand their research efforts and accelerate the development of precision medicines.
The extended partnership highlights the growing role of human genetics, large-scale biological data and artificial intelligence in pharmaceutical research. By combining Genomics’ genetic research capabilities with Vertex’s drug development expertise, the companies aim to improve the discovery of new medicines for diseases with significant unmet medical needs.
The agreement also reinforces the importance of long-term partnerships between technology-driven biotechnology companies and pharmaceutical developers in advancing next-generation treatments.
